Cargando…

Effects of Exenatide vs. Metformin on endothelial function in obese patients with pre-diabetes: a randomized trial

BACKGROUND: Glucagon like peptide-1 (GLP-1) receptor agonist treatment may improve endothelial function via direct and indirect mechanisms. We compared the acute and chronic effects of the GLP-1 receptor agonist exenatide vs. metformin on endothelial function in patients with obesity and pre-diabete...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kelly, Aaron S, Bergenstal, Richard M, Gonzalez-Campoy, J Michael, Katz, Harold, Bank, Alan J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3434036/ https://www.ncbi.nlm.nih.gov/pubmed/22681705 http://dx.doi.org/10.1186/1475-2840-11-64

Ejemplares similares

Effects of exenatide on postprandial vascular endothelial dysfunction in type 2 diabetes mellitus
por: Torimoto, Keiichi, et al.
Publicado: (2015)

Exenatide with Metformin Ameliorated Visceral Adiposity and Insulin Resistance
por: Du, Xuan, et al.
Publicado: (2018)

Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study
por: Simó, Rafael, et al.
Publicado: (2015)

Comparison of Exenatide and Metformin Monotherapy in Overweight/Obese Patients with Newly Diagnosed Type 2 Diabetes
por: Liu, Jia, et al.
Publicado: (2017)

Short-term combined treatment with exenatide and metformin for overweight/obese women with polycystic ovary syndrome
por: Ma, Rui-Lin, et al.
Publicado: (2021)

Randomized Trial of Continuous Subcutaneous Delivery of Exenatide by ITCA 650 Versus Twice-Daily Exenatide Injections in Metformin-Treated Type 2 Diabetes
por: Henry, Robert R., et al.
Publicado: (2013)

Exenatide in obesity with accelerated gastric emptying: a randomized, pharmacodynamics study
por: Acosta, Andres, et al.
Publicado: (2015)

Efficacy and safety of exenatide once‐weekly vs exenatide twice‐daily in Asian patients with type 2 diabetes mellitus
por: Ji, Linong, et al.
Publicado: (2013)

The effects of empagliflozin vs metformin on endothelial microparticles in overweight/obese women with polycystic ovary syndrome
por: Javed, Zeeshan, et al.
Publicado: (2020)

Effects of exenatide on cardiac function, perfusion, and energetics in type 2 diabetic patients with cardiomyopathy: a randomized controlled trial against insulin glargine
por: Chen, Weena J. Y., et al.
Publicado: (2017)

The Effects of Exenatide and Metformin on Endothelial Function in Newly Diagnosed Type 2 Diabetes Mellitus Patients: A Case–Control Study
por: Hu, Yanjin, et al.
Publicado: (2018)

Effects of Exercise, Metformin, Pioglitazone and Exenatide Treatment on Inflammation Induced Insulin Resistance and Ubiquitin Proteasome System in Diabetes and Obesity
por: Akarsu, Ersin, et al.
Publicado: (2021)

DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide
por: Wysham, C, et al.
Publicado: (2011)

Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study
por: Gill, Anne, et al.
Publicado: (2010)

Metformin improves circulating endothelial cells and endothelial progenitor cells in type 1 diabetes: MERIT study
por: Ahmed, Fahad W., et al.
Publicado: (2016)

Effects of Exenatide and Lifestyle Modification on Body Weight and Glucose Tolerance in Obese Subjects With and Without Pre-Diabetes
por: Rosenstock, Julio, et al.
Publicado: (2010)

Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes
por: Ratner, Robert, et al.
Publicado: (2011)

Exenatide induces aortic vasodilation increasing hydrogen sulphide, carbon monoxide and nitric oxide production
por: Sélley, Eszter, et al.
Publicado: (2014)

Development of Osteoarthritis in Adults With Type 2 Diabetes Treated With Metformin vs a Sulfonylurea
por: Baker, Matthew C., et al.
Publicado: (2023)

Comparison of exenatide alone or combined with metformin versus metformin in the treatment of polycystic ovaries: a systematic review and meta-analysis
por: Hu, Yan, et al.
Publicado: (2023)

The synergistic effects of saxagliptin and metformin on CD34+ endothelial progenitor cells in early type 2 diabetes patients: a randomized clinical trial
por: Dore, Fiona J., et al.
Publicado: (2018)

Once-Weekly Exenatide Enhances Weight Loss Maintenance in Adolescents with Severe Obesity: A Randomized, Placebo-Controlled Trial
por: Fox, Claudia K, et al.
Publicado: (2021)

The Effectiveness and Safety of Exenatide Versus Metformin in Patients with Polycystic Ovary Syndrome: A Meta-Analysis of Randomized Controlled Trials
por: Ye, Zheng-Rong, et al.
Publicado: (2023)

Exenatide can inhibit calcification of human VSMCs through the NF-kappaB/RANKL signaling pathway
por: Zhan, Jun-Kun, et al.
Publicado: (2014)

Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly alone, or dapagliflozin alone added to metformin monotherapy in subgroups of patients with type 2 diabetes in the DURATION‐8 randomized controlled trial
por: Frías, Juan P., et al.
Publicado: (2018)

Metformin and sulodexide restore cardiac microvascular perfusion capacity in diet-induced obese rats
por: van Haare, Judith, et al.
Publicado: (2017)

The effects of vildagliptin compared with metformin on vascular endothelial function and metabolic parameters: a randomized, controlled trial (Sapporo Athero-Incretin Study 3)
por: Kitao, Naoyuki, et al.
Publicado: (2017)

The exenatide analogue AC3174 attenuates hypertension, insulin resistance, and renal dysfunction in Dahl salt-sensitive rats
por: Liu, Que, et al.
Publicado: (2010)

Evolution of Exenatide as a Diabetes Therapeutic
por: Bhavsar, Sunil, et al.
Publicado: (2013)

Comparison of the effects of twice-daily exenatide and insulin on carotid intima-media thickness in type 2 diabetes mellitus patients: a 52-week randomized, open-label, controlled trial
por: Zhang, Jie, et al.
Publicado: (2020)

Evaluation of the cost effectiveness of exenatide versus insulin glargine in patients with sub-optimally controlled Type 2 diabetes in the United Kingdom
por: Woehl, Anette, et al.
Publicado: (2008)

Effects of metformin and Exenatide on insulin resistance and AMPKα-SIRT1 molecular pathway in PCOS rats
por: Tao, Xin, et al.
Publicado: (2019)

A real world comparison of sulfonylurea and insulin vs. incretin-based treatments in patients not controlled on prior metformin monotherapy
por: Gitt, Anselm K, et al.
Publicado: (2015)

Pancreatitis Incidence in the Exenatide BID, Exenatide QW, and Exenatide QW Suspension Development Programs: Pooled Analysis of 35 Clinical Trials
por: Vetter, Marion L., et al.
Publicado: (2019)

Temporal Changes in Obesity-Related Medication After Bariatric Surgery vs No Surgery for Obesity
por: Kauppila, Joonas H., et al.
Publicado: (2023)

Effects of exenatide on urinary albumin in overweight/obese patients with T2DM: a randomized clinical trial
por: Kang, Chao, et al.
Publicado: (2021)

Exenatide modulates tumor–endothelial cell interactions in human ovarian cancer cells
por: Kosowska, Agnieszka, et al.
Publicado: (2017)

Population pharmacokinetics of exenatide
por: Cirincione, Brenda, et al.
Publicado: (2016)

Effects of Exenatide on Measures of β-Cell Function After 3 Years in Metformin-Treated Patients With Type 2 Diabetes
por: Bunck, Mathijs C., et al.
Publicado: (2011)

Activation of AMP-activated protein kinase by metformin protects human coronary artery endothelial cells against diabetic lipoapoptosis
por: Eriksson, Linnéa, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_8baheb4sn21gt852mhkdputkh1